Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study

INTRODUCTION: Investigate the effects of switching from two times per day exenatide to once-weekly exenatide administered by autoinjector (exenatide once-weekly suspension by autoinjector (QWS-AI)) or treatment with exenatide QWS-AI for 1 year. RESEARCH DESIGN AND METHODS: In this phase III open-lab...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Open Diabetes Res Care
Päätekijät: Wysham, Carol H, Rosenstock, Julio, Vetter, Marion L, Wang, Hui, Hardy, Elise, Iqbal, Nayyar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Obesity Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549491/
https://ncbi.nlm.nih.gov/pubmed/33037036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-000773
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia